Medtronic Touts AdaptivCRT Algorithm Economic Benefits With New Heart Failure Data
This article was originally published in The Gray Sheet
Executive Summary
Results of ADAPTIVE CRT trial show that resynchronization therapy devices with Medtronic's AdaptivCRT algorithm reduce heart failure hospitalizations.
You may also be interested in...
Heart Failure Devices: Raising Roadblocks To Readmission
A new Medicare cost-control program aimed at reducing costly hospital readmissions has heart failure squarely in the cross-hairs, and the consequences could mean hundreds of thousands of dollars in lost Medicare revenue for hospitals that fail to meet the new readmission standards. As a result, providers are scrambling to implement programs to assess and reduce heart failure readmissions, and a growing number of device companies are touting a variety of technologies they believe could help them achieve that goal.
Huma Secures EU MDR Approval For Medtech Software That Can Be Used In Any Disease
Huma Therapeutics has secured the first ever EU regulatory approval for a “disease agnostic” class IIb medtech software platform. CEO Dan Vahdat tells Medtech Insight how the product can be configured to monitor patients with any condition.
Moderna CEO Hearing Highlights Dissatisfaction With Patient Assistance Programs
There was bipartisan agreement that Moderna need to ensure that its patient assistance program will be easily accessible for under- and uninsured patients once the US switches to a commercial market for COVID vaccines – a sign of broader frustration with industry copay support initiatives.